A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C

Koh, Christopher; Dubey, Preeti; Han, Mingda; Walter, Peter J.; Garraffo, H. Martin; Surana, Pallavi; Southall, Noel; Borochov, N.; Uprichard, Susan L.; Cotler, Scott J.; Etzion, Ohad; Heller, Theo; Dahari, Harel; Liang, T. Jake

doi:10.1016/j.antiviral.2019.01.017

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A small study involving CCZ treatment of 24 adult patients with a median HCV RNA load of 6.3 log IU/mL indicated that the drug used as monotherapy (2mg/kg x 28 days) produced no significant reduction in viremia (p= 0.69) [109]. However, 7/12 (58%) patients treated with CCZ+ ribavirin (RBV) had >3-fold decrease in HCV RNA.…”

Section: Hepatitis C Virus (Hcv)mentioning

confidence: 99%

Current status of antihistamine drugs repurposing for infectious diseases

Travi¹

2022

Medicine in Drug Discovery

View full text Add to dashboard Cite

Section: Hepatitis C Virus (Hcv)mentioning

confidence: 99%

Current status of antihistamine drugs repurposing for infectious diseases

Travi¹

2022

Medicine in Drug Discovery

View full text Add to dashboard Cite

“…And in vivo studies further demonstrated its efficacy in inhibiting genotypes 1b and 2a HCV infection [ 10 ]. In addition, the results of a randomized proof-of-concept clinical trial showed that chlorcyclizine had some anti-HCV effects, and most notably in combination with ribavirin, a broad-spectrum antiviral agent [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Revisiting potential value of antitumor drugs in the treatment of COVID-19

Zheng

Zeng

et al. 2022

Cell Biosci

View full text Add to dashboard Cite

Since an outbreak started in China in 2019, coronavirus disease 2019 (COVID-19) has rapidly become a worldwide epidemic with high contagiousness and caused mass mortalities of infected cases around the world. Currently, available treatments for COVID-19, including supportive care, respiratory support and antiviral therapy, have shown limited efficacy. Thus, more effective therapeutic modalities are highly warranted. Drug repurposing, as an efficient strategy to explore a potential broader scope of the application of approved drugs beyond their original indications, accelerates the process of discovering safe and effective agents for a given disease. Since the outbreak of COVID-19 pandemic, drug repurposing strategy has been widely used to discover potential antiviral agents, and some of these drugs have advanced into clinical trials. Antitumor drugs compromise a vast variety of compounds and exhibit extensive mechanism of action, showing promising properties in drug repurposing. In this review, we revisit the potential value of antitumor drugs in the treatment of COVID-19 and systematically discuss their possible underlying mechanisms of the antiviral actions.

show abstract

“…They previously demonstrated that CCZ shows promising efficacy for inhibiting HCV infection in mice and has a synergistic effect with multiple DAAs including ribavirin (RBV) in vitro, without significant cytotoxicity caused by drug interaction (He et al, 2015). However, in a recent small clinical trial (ClinicalTrials.gov number: NCT02118012), CCZ demonstrated limited anti-HCV effects, mostly in combination with RBV, although that may be due to a lack of genotype 2 infected patients in the trial (Koh et al, 2019).…”

mentioning

confidence: 99%